Skip to main content
NewslettersWatchlist

Cybin Inc(CYBN-NE)
Cboe CA

Today's Change
Real-Time Last Update
Day Low0.4650
Day High0.5100
Open:0.5100
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Efficacy Milestone and Delivering Prompt Relief from Depression Symptoms with a Single Dose - Comprehensive Topline Data Anticipated by Q4 2023
Newsfile
Cybin to Acquire Small Pharma Inc.
Business Wire
Cybin to Participate at the 26th Annual Milken Institute Global Conference
Business Wire
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
Business Wire
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder in Psychedelics Discussions
Business Wire
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
Business Wire
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Business Wire
Cybin Announces Streamlined Clinical Alignment
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report
Business Wire
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Business Wire
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Business Wire
Cybin to Host Virtual R&D Day on February 28, 2023
Business Wire
Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Selects Generalized Anxiety Disorder as Target Indication for CYB004
Business Wire
Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Releases Update on Clinical Programs
Business Wire
Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) CEO Highlights 2022 as ‘Momentous Year’
Business Wire
Cybin Highlights 2022 Accomplishments and Milestones
Business Wire
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Q2 Results, Business Highlights
Business Wire
Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022
Business Wire
Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights
Business Wire
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Announces Schedule for Upcoming Events
Business Wire
Cybin to Participate in the Jefferies London Healthcare Conference and Upcoming Investor Events
Business Wire
Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators
Business Wire
Cybin’s EMBARK Program Announces Graduation of Facilitators
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Working to Create the Best Psychedelic Therapies for Patients

Profile

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.